Moving Beyond Mu With Kappa Opioid Receptor Agonists-Leaving the Baggage Behind

Supported by Cara Therapeutics

This activity is not certified for credit.

Friday, September 9

Start Time

End Time

Castellana Ballroom
Level 3

Program Description
Traditional mu opioid receptor agonists play an important role in the management of acute and chronic pain. However, their use is associated with the public health epidemics of abuse, misuse, and diversion, as well mortality and morbidity due to opioid-associated overdose and respiratory depression. In addition, mu opioid receptor agonists cause other adverse effects, such as nausea and vomiting, which can delay postoperative recovery and increase healthcare costs.

A novel peripherally acting kappa opioid receptor agonist, CR845, is currently in Phase 3 trials for postoperative pain (I.V. CR845) and in Phase 2 trials for chronic pain (Oral CR845). Because of its unique pharmacologic properties, CR845 has been shown to produce significant analgesia with low abuse potential and little to no traditional mu opioid side effects, such as nausea and vomiting, pruritus, and respiratory depression.

Please join us for this PDM program, where the faculty will describe the pharmacology of CR845, present clinical data for CR845, and consider CR845’s potential place in analgesic therapy for acute and chronic pain.

Learning Objectives
After attending this PDM program, participants should be better able to:

  • Recognize the unmet clinical needs and safety concerns with the current analgesic landscape
  • Describe the unique pharmacologic properties of a new class of opioid—the peripherally acting kappa opioid receptor agonist, CR845
  • Identify the potential benefits of oral CR845 in the management of acute and chronic pain, and I.V. CR845 for post-operative acute pain

Joseph Stauffer, DO, MBA
Michael J. Brennan, MD

Registration Website

Contact Name
Samantha Libby-Cap

Contact Phone
(860) 575-5360

Contact email

Related Content